CD38 and B-cell chronic lymphocytic leukemia: Daratumumab also shows preclinical anti‐tumor activity against CD38‐expressing CLL tumor cells and inhibits adhesion and migration of CLL tumor cells in the tumor microenvironment 133, 134, indicating that CD38‐targeting antibodies may also be of value in the treatment of CD38‐positive CLL.